CAR-T細胞療法の市場規模、シェア、動向分析レポート：製品別、適応症別、最終用途別、地域別、セグメント予測、2025～2030年

CAR-T細胞療法市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のCAR-T細胞療法の市場規模は2030年までに159億7,000万米ドルに達し、2025～2030年までのCAGRは22.2％で拡大すると推定されています。CAR-T細胞療法は、リンパ腫、多発性骨髄腫、白血病などの血液がんの治療において、患者の免疫系を利用してがん細胞を死滅させるというパラダイムシフトを提示します。新興諸国における多発性骨髄腫などのがん種の有病率の上昇が市場を牽引しています。製品承認や集中的な医薬品パイプラインという形で規制当局のサポートが充実していることも、業界をさらに強化しています。例えば、米国国立医学図書館の2023年4月の発表によると、CAR-T細胞に関連する約310の研究が、世界各地で初期第I相、第I相、第II相にわたって実施されています。

世界中で治療をカバーするために、さまざまな企業が地理的拡大とともに戦略的提携を結んでいます。そのため、企業は、血液がんの潜在的な治療法や処置が利用できない国々における地理的範囲を拡大する戦略を採用しています。例えば、2022年8月31日、Gilead傘下の医療企業Kiteは、サウジアラビア、ブラジル、シンガポールでのCAR-T細胞療法の拡大を発表しました。同社は、シンガポールで1,000例以上の非ホジキンリンパ腫（NHL）の発生を報告し、サウジアラビアでは約1,700例が診断されています。同様にブラジルでは毎年約12,000例の非ホジキンリンパ腫が見つかっています。

COVID-19の大流行により、患者へのCAR-T細胞療法の施行が困難になっており、特にパンデミックの初期には多くの病院や診療所がCOVID-19患者で溢れかえっていました。多くの病院では、COVID-19患者のためのリソースを確保するために、CAR-T細胞療法を含む選択的治療を延期または中止しなければなりませんでした。さらに、CAR-T細胞療法にはサイトカイン放出症候群（CRS）などの重大な副作用があり、発熱、低血圧、COVID-19の症状を模倣した臓器障害を引き起こす可能性があるため、治療には問題がありました。

新興諸国の病院やがん治療センターでは、CAR-T細胞の導入が進んでいます。これらのセンターは、費用と時間の効率的ながん治療が市場の全体的な成長を可能にしています。例えば、2022年8月、メキシコのがん治療センターであるImmunotherapy Instituteは、米国とカナダの患者にCAR-T細胞を提供する事業を開始しました。同様に、イスラエルでは、全プロセスを自社内で行うため、治療が約10日で完了し、顕著なコスト削減を実現しています。

新興国における熟練した専門家の不足と治療に伴う高コストが、市場成長への課題として残っています。しかし、認知度の向上と技術的に先進的なCAR-T細胞療法に対する承認の増加は、これらの課題を軽減し、予測期間中の市場成長に貢献すると予想されます。米国がん治療センター（Cancer Treatment Centers of America）によると、2023年現在、6つのCAR-T細胞療法が血液がんの治療薬として米国FDAから承認されています。

CAR-T細胞療法市場レポートハイライト

• 製品別では、Yescarta（アキシカブタジェンシロレウセル）が2024年に50.0%のシェアを占め、市場を独占しました。Yescartaの高い使用率は、再発B細胞大リンパ腫に罹患している成人における好調なパフォーマンスと生存率の改善に起因しています。
• 適応症別ではリンパ腫が2024年にCAR-T細胞療法市場で最大のシェアを占めました。同分野の市場浸透率の高さは、世界の同疾患の有病率の高さに起因しています。加えて、CD-19抗原の排除に向けた市場プレイヤーの強力な製品フォーカスも成長を後押ししています。
• 最終用途別では、病院分野が2024年にCAR-T細胞療法業界で最大のシェアを占めました。さらに、病院内ラボはプロセスを迅速化するため、高いシェアを獲得しています。
• 北米は2024年に62.1%の最大シェアを占めました。シェアが大きい主な理由は、患者数の多さと、迅速な承認と強固な医療保険適用による一般的かつ複雑なヘルスケアへの全体的なアクセスにあります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 CAR-T細胞療法市場の変数、動向、範囲

• 市場系統展望
  • 親市場展望
  • 関連/補助市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• CAR-T細胞療法市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 CAR-T細胞療法市場：製品別、推定・動向分析

• 製品セグメントダッシュボード
• CAR-T細胞療法市場：製品変動分析
• 世界のCAR-T細胞療法市場規模と動向分析：製品別、2018～2030年
• Abecma（イデカブタゲンビクルセル）
• Breyanzi （リソカブタゲンマラロイセル）
• Carvykti（シルタカブタゲンオートロイセル）
• Kymriah（ティサゲンレクルセル）
• Tecartus（ブレクスカブタゲンオートロイセル）
• Yescarta（アキシカブタゲンシロレウセル）
• その他

第5章 CAR-T細胞療法市場：適応症別、推定・動向分析

• 疾患適応セグメントダッシュボード
• CAR-T細胞療法市場：適応症変動分析
• 世界のCAR-T細胞療法市場規模と動向分析：適応症別、2018～2030年
• 白血病
• リンパ腫
• 多発性骨髄腫
• その他

第6章 CAR-T細胞療法市場：最終用途別、推定・動向分析

• 製品セグメントダッシュボード
• CAR-T細胞療法市場：最終用途変動分析
• 世界のCAR-T細胞療法市場規模と動向分析：最終用途別、2018～2030年
• 病院
• がん治療センター

第7章 CAR-T細胞療法市場：地域別、推定・動向分析

• 地域市場ダッシュボード
• 地域別市場シェア分析、2024年および2030年
• 地域別CAR-T細胞療法市場
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
• アジア太平洋
  • 日本
  • 中国
• その他の国

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • Key Company Heat Map Analysis, 2024
• 企業プロファイル
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Gilead Sciences, Inc.
  • Johnson &Johnson Services, Inc.
  • JW Therapeutics（Shanghai）Co., Ltd.
  • bluebird bio, Inc.
  • Merck &Co., Inc.
  • Sangamo Therapeutics
  • Sorrento Therapeutics, Inc.
  • GSK plc.

List of Tables

• Table 1 List of abbreviations
• Table 2 North America CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
• Table 3 North America CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
• Table 4 North America CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 5 North America CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
• Table 6 U.S. CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
• Table 7 U.S. CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 8 U.S. CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
• Table 9 Canada CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
• Table 10 Canada CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 11 Canada CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
• Table 12 Europe CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
• Table 13 Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
• Table 14 Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 15 Europe CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
• Table 16 Germany CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
• Table 17 Germany CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 18 Germany CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
• Table 19 UK CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
• Table 20 UK CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 21 UK CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
• Table 22 Asia Pacific CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
• Table 23 Asia Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
• Table 24 Asia Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 25 Asia Pacific CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
• Table 26 Japan CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
• Table 27 Japan CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 28 Japan CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
• Table 29 China CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
• Table 30 China CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 31 China CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
• Table 32 Rest of World CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
• Table 33 Rest of World CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
• Table 34 Rest of World CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
• Table 35 Rest of World CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 CAR T-cell therapy market: Market outlook
• Fig. 10 CAR T-cell therapy competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 CAR T-cell therapy market driver impact
• Fig. 16 CAR T-cell therapy market restraint impact
• Fig. 17 CAR T-cell therapy market strategic initiatives analysis
• Fig. 18 CAR T-cell therapy market: Product movement analysis
• Fig. 19 CAR T-cell therapy market: Product outlook and key takeaways
• Fig. 20 Abecma (idecabtagene vicleucel) market estimates and forecast, 2018 - 2030
• Fig. 21 Breyanzi (lisocabtagene maraleucel) market estimates and forecast, 2018 - 2030
• Fig. 22 Carvykti (ciltacabtagene autoleucel) market estimates and forecast, 2018 - 2030
• Fig. 23 Kymriah (tisagenlecleucel) market estimates and forecast, 2018 - 2030
• Fig. 24 Tecartus (brexucabtagene autoleucel) market estimates and forecast, 2018 - 2030
• Fig. 25 Yescarta (axicabtagene ciloleucel) market estimates and forecast, 2018 - 2030
• Fig. 26 Other market estimates and forecast, 2018 - 2030
• Fig. 27 CAR T-cell therapy market: Disease indication movement analysis
• Fig. 28 CAR T-cell therapy market: Disease indication outlook and key takeaways
• Fig. 29 Leukemia market estimates and forecasts, 2018 - 2030
• Fig. 30 Lymphoma market estimates and forecasts,2018 - 2030
• Fig. 31 Multiple Myeloma market estimates and forecasts, 2018 - 2030
• Fig. 32 Other market estimates and forecasts, 2018 - 2030
• Fig. 33 CAR T-cell therapy market: End use movement analysis
• Fig. 34 CAR T-cell therapy market: End use outlook and key takeaways
• Fig. 35 Hospitals CAR T-cell therapy market estimates and forecast, 2018 - 2030
• Fig. 36 Cancer Treatment Centers CAR T-cell therapy estimates and forecast, 2018 - 2030
• Fig. 37 Global CAR T-cell therapy market: Regional movement analysis
• Fig. 38 Global CAR T-cell therapy market: Regional outlook and key takeaways
• Fig. 39 North America market estimates and forecasts, 2018 - 2030
• Fig. 40 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 41 Canada market estimates and forecasts, 2018 - 2030
• Fig. 42 Europe market estimates and forecasts, 2018 - 2030
• Fig. 43 Germany market estimates and forecasts, 2018 - 2030
• Fig. 44 UK market estimates and forecasts, 2018 - 2030
• Fig. 45 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 46 Japan market estimates and forecasts, 2018 - 2030
• Fig. 47 China market estimates and forecasts, 2018 - 2030
• Fig. 48 Rest of World market estimates and forecasts, 2018 - 2030

CAR T-cell Therapy Market Growth & Trends:

The global CAR T-cell therapy market size is estimated to reach USD 15.97 billion by 2030, expanding at a CAGR of 22.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. CAR T-cell therapy presents a paradigm shift in the treatment of blood cancers such as lymphoma, multiple myeloma, and leukemia by utilizing the patient's immune system to terminate cancer cells. The rising prevalence of cancer types such as multiple myeloma in developing countries is driving the market. Rampant regulatory support in the form of product approvals and an intensive product pipeline of drugs further strengthens the industry. For instance, as per the U.S. National Library of Medicine April 2023, around 310 studies pertinent to CAR T-cells are being conducted across early phase I, phase I, and phase II in various parts of the world.

Various players are entering into strategic partnerships along with geographic expansion to necessitate therapy coverage across the world. Thereby, companies are adopting strategies to increase the geographical footprint in countries without access to potential cures or treatments for blood cancers. For instance, on August 31, 2022, Kite, a medical company operating under Gilead announced the expansion of CAR T-cell therapy in regions of Saudi Arabia, Brazil, and Singapore. The company reported an occurrence of 1000 or higher cases of non-Hodgkin lymphoma (NHL) in Singapore, while around 1700 cases of the disease are diagnosed in Saudi Arabia. Similarly, in Brazil, around 12000 cases of NHL are found each year.

The COVID-19 pandemic has made it difficult to administer CAR T-cell therapy to patients, particularly in the early stages of the pandemic when many hospitals and clinics were overwhelmed with COVID-19 patients. Many hospitals had to postpone or cancel elective procedures, including CAR T-cell therapy, to free up resources for COVID-19 patients. In addition, CAR T-cell therapy has significant side effects, including cytokine release syndrome (CRS), which can cause fever, low blood pressure, and organ damage which mimics the symptoms of COVID-19, thereby, curating problems to treat for condition.

Moreover, hospitals and cancer care centers emerging in developing countries are progressing with the adoption of CAR T-cells. These centers thrive as cost and time-efficient cancer treatments allow the market to grow holistically. For instance, in August 2022, Immunotherapy Institute, a cancer treatment center in Mexico began operations to offer CAR T-cells for American and Canadian patients. Similarly, in Israel, the therapy can be expedited in about 10 days owing to the entire process being conducted in-house, with notable cost reductions.

The lack of skilled professionals in emerging nations coupled with the high cost associated with the therapy remain challenges to market growth. However, rising awareness and increasing approvals for technologically advanced CAR T-cell therapy are anticipated to mitigate these challenges and contribute to market growth over the forecast period. According to Cancer Treatment Centers of America, six CAR T-cell therapies were approved by U.S. FDA for the treatment of blood cancers as of 2023.

CAR T-cell Therapy Market Report Highlights:

• By product, the Yescarta (axicabtagene ciloleucel) segment dominated the market with a share of 50.0% in 2024. The high usage of Yescarta can be attributed to strong performance and improved survivability in adults suffering from relapsed B-cell large lymphoma
• The lymphoma segment held the largest CAR T-cell therapy market share in 2024. The high penetration of the market segment owes itself to the significant prevalence of the condition across the world. Additionally, the strong product focus by market players to eliminate the CD-19 antigen drives growth
• By end-use, the hospital segment held the largest share of CAR T-cell therapy industry in 2024 due to the robust presence of fiscal and operational resources. Additionally, in-house labs for hospitals expedite the process faster, helping to gain a strong share
• North America accounted for the largest share of 62.1% in 2024. The primary reason for a sizable share can be attributed to the patient volume and overall access to general and complex healthcare, with speedy approvals and robust medical insurance coverage

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Disease Indication
  • 1.2.3. End Use
  • 1.2.4. Regional Scope
  • 1.2.5. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Outlook
  • 2.2.2. Disease indication Outlook
  • 2.2.3. End Use Outlook
  • 2.2.4. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. CAR T-cell Therapy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. CAR T-cell Therapy Market Analysis tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. CAR T-cell Therapy Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. CAR T-cell Therapy Market: Product Movement Analysis
• 4.3. Global CAR T-cell Therapy Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
• 4.4. Abecma (idecabtagene vicleucel)
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Breyanzi (lisocabtagene maraleucel)
  • 4.5.1. ket Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.6. Carvykti (ciltacabtagene autoleucel)
  • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.7. Kymriah (tisagenlecleucel)
  • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.8. Tecartus (brexucabtagene autoleucel)
  • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.9. Yescarta (axicabtagene ciloleucel)
  • 4.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. CAR T-cell Therapy Market: Disease Indication Estimates & Trend Analysis

• 5.1. Disease Indication Segment Dashboard
• 5.2. CAR T-cell Therapy Market: Disease Indication Movement Analysis
• 5.3. Global CAR T-cell Therapy Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
• 5.4. Leukemia
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Lymphoma
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Multiple Myeloma
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. CAR T-cell Therapy Market: End Use Estimates & Trend Analysis

• 6.1. Product Segment Dashboard
• 6.2. CAR T-cell Therapy Market: End-use Movement Analysis
• 6.3. Global CAR T-cell Therapy Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Cancer Treatment Centers
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. CAR T-cell Therapy Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2024 & 2030
• 7.3. Continuous Bioprocessing Market By Region: Key Takeaways
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key Country Dynamics
    • 7.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.4.1.3. Competitive Scenario
    • 7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Germany
    • 7.5.1.1. Key Country Dynamics
    • 7.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.1.3. Competitive Scenario
    • 7.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key Country Dynamics
    • 7.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.1.3. Competitive Scenario
    • 7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.7. Rest of World
  • 7.7.1.1. Key Country Dynamics
  • 7.7.1.2. Regulatory Framework/ Reimbursement Structure
  • 7.7.1.3. Competitive Scenario
  • 7.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key Company Heat Map Analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Bristol-Myers Squibb Company
    • 8.4.1.1. Company Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Novartis AG
    • 8.4.2.1. Company Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Gilead Sciences, Inc.
    • 8.4.3.1. Company Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Johnson & Johnson Services, Inc.
    • 8.4.4.1. Company Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. JW Therapeutics (Shanghai) Co., Ltd.
    • 8.4.5.1. Company Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. bluebird bio, Inc.
    • 8.4.6.1. Company Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Merck & Co., Inc.
    • 8.4.7.1. Company Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Sangamo Therapeutics
    • 8.4.8.1. Company Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Sorrento Therapeutics, Inc.
    • 8.4.9.1. Company Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. GSK plc.
    • 8.4.10.1. Company Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives